Author

E. M. Dolman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Organism:zebrafish· 1

Frequent Co-Authors

J. J. Molenaar· 2 shared A. Eggermont· 1 shared A. Louwagie· 1 shared B. De Wilde· 1 shared B. Decaesteker· 1 shared B. Koopmans· 1 shared C. Bartenhagen· 1 shared C. Nunes· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. J. Molenaar

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastoma

C. Nunes, L. Depestel, L. M. Mus, K. M. Keller, L. Delhaye, A. Louwagie, M. Rishfi, E. M. Dolman, V. Olexiouk, C. Bartenhagen, F. Devloed, E. Sanders, A. Eggermont, J. Van Laere, E. De Smet, , F. Speleman

This study identifies RRM2 as a therapeutic target in high-risk neuroblastoma, showing that combined RRM2 and CHK1 inhibition synergistically reduces tumor growth.

bioRxiv · Nov 25, 2020 · PreprintCancer Biology

MEK inhibition causes Bim stabilization and sensitivity to Bcl2 family member inhibitors in RAS-MAPK mutated neuroblastoma

T. F. Eleveld, L. Vernooij, L. Schild, B. Koopmans, L. K. Alles, M. E. Ebus, P. G. van Sluis, H. N. Caron, J. Koster, R. Versteeg, E. M. Dolman, J. J. Molenaar

The paper identifies MEK inhibition combined with BCL2 family inhibitors as a potent treatment for RAS-MAPK mutated neuroblastoma by stabilizing Bim and increasing sensitivity to Bcl2 inhibitors.

bioRxiv · Feb 12, 2020 · PreprintCancer Biology